Effects of therapy using the Celacade system on structural and functional cardiac remodelling in rats following myocardial infarction

Canadian Journal of Cardiology

Volumn 25, Issue 7, 2009, Pages

  Zhang, Mei Luo ^a   Mei, Jie ^b   Archer, Lori Anne ^a   Obayashi, Masakazu ^c   Diao, Ni ^a   Stuyvers, Bruno ^a   ter Keurs, Henk E D J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b HEALTH CANADA   (Canada)

^c YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Congestive heart failure; Contractility; Excitation contraction coupling; Muscle; Myocardial infarction

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; CYTOKINE; INTERLEUKIN 6; OZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELACADE SYSTEM DEVICE; CORONARY ARTERY LIGATION; CYTOKINE PRODUCTION; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INFARCTION; HEART SIZE; INOTROPISM; LASER DIFFRACTION; MALE; MEDICAL INSTRUMENTATION; NONHUMAN; PROTEIN EXPRESSION; RAT; SARCOMERE LENGTH; STRAIN GAUGE TRANSDUCER; ANALYSIS OF VARIANCE; ANIMAL; BIOSYNTHESIS; BROWN NORWAY RAT; DISEASE MODEL; ECHOGRAPHY; HEART CONTRACTION; HEART MUSCLE; HEAT; IMMUNOLOGY; LEWIS RAT; PATHOLOGY; TIME; ULTRAVIOLET RADIATION;

ANALYSIS OF VARIANCE; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; HOT TEMPERATURE; INTERLEUKIN-6; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; OZONE; RATS; RATS, INBRED BN; RATS, INBRED LEW; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; ULTRAVIOLET RAYS;

EID: 67849119471     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70510-0     Document Type: Article

References (31)

1. Davidoff AW, Boyden PA, Schwartz K, et al. Congestive heart failure after myocardial infarction in the rat: Cardiac force and spontaneous sarcomere activity. Ann N Y Acad Sci 2004;1015:84-95.
2. Obayashi M, Xiao BL, Stuyvers BD, et al. Spontaneous diastolic contractions and phosphorylation of the cardiac ryanodine receptor at serine-2808 in congestive heart failure in rat. Cardiovasc Res 2006;69:140-51.
3. Tremblay J, Chen HF, Peng JZ, et al. Renal ischemia-reperfusion injury in the rat is prevented by a novel immune modulation therapy. Transplantation 2002;74:1425-33.
4. Babaei S, Stewart DJ, Picard P, Monge JC. Effects of VasoCare therapy on the initiation and progression of atherosclerosis. Atherosclerosis 2002;162:45-53.
5. Torre-Amione G, Sestier FO, Radovancevic B, Young J. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure - results of a randomized, controlled, phase II trial. J Am Coll Cardiol 2004;44:1181-6.
6. Coletta AP, Nikitin N, Clark AL, Cleland JG. Clinical trials update from the American Heart Association meetmg: PROSPER, DIAL, home care monitoring trials, immune modulation therapy, COMPANION and anaemia in heart failure. Eur J Heart Fail 2003;5:95-9.
7. McGrath C, Robb R, Lucas AJ, et al. A randomised, double blind, placebo-controlled study to determine the efficacy of immune modulation therapy in the treatment of patients suffering from peripheral arterial occlusive disease with intermittent claudication. Eur J Vasc Endovasc Surg 2002;23:381-7.
8. Cooke ED, Pockley AG, Tucker AT, Kirby JD, Bolton AE. Treatment of severe Raynaud's syndrome by injection of autologous; blood pretreated by heating, ozonation and exposure to ultraviolet light (H-O-U) therapy. Int Angiol 1997;16:250-4.
9. Johns TNP, Olson BJ. Experimental myocardial infarction. I. A method of coronary occlusion in small animals. Ann Surg 1954;140:675-82.
10. Francis J, Chu Y, Johnson AK, Weiss RM, Felder RB. Acute myocardial infarction induces hypothalamic cytokine synthesis. Am J Physiol Heart Circ Physiol 2004;286:H2264-71.
11. Davidoff AW. Cardiac muscle function after coronary artery ligation in rat. PhD thesis, University of Calgary, 2002.
12. Terkeurs HEDJ, Rijnsburger WH, Vanheuningen R, Nagelsmit MJ. Tension development and sarcomere-length in rat cardiac trabeculae - evidence of length-dependent activation. Circ Res 1980;46:703-14.
13. 2+. J Physiol 1997;502:661-77.
14. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 1991;260:H1406-14.
15. Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell 2000;101:365-76.
16. 2+/ calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res 2004;94:e61-e70.
17. Xiao B, Zhong G, Obayashi M, et al. Ser-2030, but not Ser-2808, is the major phosphorylation site in cardiac ryanodine receptors responding to protein kinase A activation upon beta-adrenergic stimulation in normal and failing hearts. Biochem J 2006;396:7-16.
18. Yano M, Ono K, Ohkusa T, et al. Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure. Circulation 2000;102:2131-6.
19. 2+-leak induced by oxidative stress. Circ J 2006;70:777-86.
20. Holubarsch C, Ruf T, Goldstein DJ, et al. Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere levels. Circulation 1996;94:683-9.
21. Endoh M. Force-frequency relationship in intact mammalian ventricular myocardium: Physiological and pathophysiological relevance. Eur J Pharmacol 2004;500:73-86.
22. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation 1992;85:1743-50.
23. Schouten VJ, Ter Keurs HE. The force-frequency relationship in rat myocardium. The influence of muscle dimensions. Pflugers Arch 1986;407:14-7.
24. Bers DM. Calcium fluxes involved in control of cardiac myocyte contraction. Circ Res 2000;87:275-81.
25. Hund TJ, Rudy Y. A role for calcium/calmodulin-dependent protein kinase II in cardiac disease and arrhythmia. Handb Exp Pharmacol 2006;201-220.
26. Deten A, Zimmer HG. Heart function and cytokine expression is similar in mice and rats after myocardial infarction but differences occur in TNF alpha expression. Pflug Arch Eur J Phy 2002;445:289-96.
27. Deten A, Volz HC, Briest W, Zimmer HG. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 2002;55:329-40.
28. Irwin MW, Mak S, Mann DL, et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation 1999;99:1492-8.
29. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-92.
30. Ikeuchi M, Tsutsui H, Shiomi T, et al. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 2004;64:526-35.
31. Okada H, Takemura G, Kosai K, et al. Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure. Circulation 2005;111:2430-7.